Projected Earnings Date: 2025-08-05    (Delayed quote data   2025-07-11)
Last
 11.22
Change
 ⇓ -0.13   (-1.15%)
Volume
  1,227,241
Open
 11.70
High
 11.73
Low
 11.19
8EMA (Daily)
 11.97
40EMA (Daily)
 12.50
50EMA (Daily)
 12.26
STO (Daily)
 2.070
MACD Hist (Daily)
 -0.843
8EMA (Weekly)
 12.080
40EMA (Weekly)
 10.11
50EMA (Weekly)
 9.63
STO (Weekly)
 66.048
MACD Hist (Weekly)
 -0.015
Cormedix Inc is a biopharmaceutical company which focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. It has in-licensed to develop and commercialize Neutrolin, which is a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings such as hemodialysis, total parenteral nutrition, and oncology. The Neutrolin product is designed to target unmet medical need.
optionchance optionchance
Home | Chart and Research | Education | About Us  

Disclaimer: All information provided is for informational purposes only and not intended for trading purposes or advice. The quotes and charts are not real time and have delays of at least 20 minutes. Data accuracy cannot be guaranteed as errors will occur. Please do not rely on the above information to make your stock/option trades. Neither OptionChance.com nor any of independent data providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein.

Questions or Comments: support@optionchance.com
Copyright © 2025 OptionChance.com